This activity is supported by an educational grant from Genentech, Inc.
Expiration Date: 9/11/2020
The integration of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy into management protocols for the treatment of neovascular retinal disease…go to activity»
Expiration Date: 8/30/2020
nAMD is an incurable disease and can lead to permanent vision loss. nAMD imposes a high burden on patients and eye care providers alike, as optimal visual outcomes have…go to activity»
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Expiration Date: 8/27/2020
The treatment of neovascular age-related macular degeneration (nAMD) has been revolutionized through the introduction of intravitreal anti–vascular endothelial growth…go to activity»
This activity is supported by independent medical education grants from Optos North America and Regeneron Pharmaceuticals, Inc.
Expiration Date: 6/1/2020
Diabetic retinopathy (DR) continues to be a leading cause of blindness. However, early diagnosis and prompt treatment with laser and/or intravitreal anti-vascular…go to activity»
This activity is supported by an educational grant from Allergan, Inc.
Expiration Date: 4/30/2020
Explore the treatment options for a patient with diabetes and blurry vision presented by Dr Roger Goldberg with faculty discussion of treatment strategies and timing to…go to activity»
This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.
Expiration Date: 3/17/2020
The medical management of glaucoma is primarily focused on lessening intraocular pressure (IOP) by reducing aqueous humor formation or improving the drainage of aqueous…go to activity»